T6BP Inhibitors
T6BP inhibitors are a class of chemical compounds that specifically target the T6BP (Tax1-binding protein 1) molecule, an adaptor protein involved in various cellular signaling pathways. These inhibitors function by interfering with the protein-protein interactions mediated by T6BP, thereby modulating critical cellular processes such as autophagy, innate immunity, and inflammation. Structurally diverse, T6BP inhibitors can bind to different domains of the T6BP protein, affecting its interaction with other proteins like ubiquitin ligases and kinase complexes. By inhibiting T6BP, these compounds can alter the ubiquitination and phosphorylation states of key signaling molecules, leading to significant changes in downstream cellular responses.
T6BP inhibitors include a range of small molecules, peptides, and analogs identified through high-throughput screening and rational design methods. The development of these inhibitors often involves incorporating functional groups that enhance binding affinity and specificity toward T6BP. Structural analyses and computational modeling are employed to understand the molecular interactions between the inhibitors and T6BP, facilitating the optimization of their potency and selectivity. Some T6BP inhibitors may exhibit cross-reactivity with other proteins in the same family, necessitating careful evaluation of their selectivity profiles. Ongoing research focuses on elucidating the detailed mechanisms of action of T6BP inhibitors, improving their chemical stability, and exploring their effects on various cellular pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide can downregulate T6BP expression by hindering the activation of NF-κB. It accomplishes this by decreasing the transcriptional activity of NF-κB on its target genes, thereby potentially reducing the mRNA levels of T6BP. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib has the potential to decrease T6BP expression through stabilization of IκB, leading to sustained inhibition of NF-κB and subsequent reduction in T6BP transcription due to diminished NF-κB nuclear presence. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
By suppressing TNF-α, a cytokine that activates NF-κB, Thalidomide can contribute to the decreased transcription of NF-κB-dependent genes such as T6BP, hence potentially reducing its expression. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide could reduce T6BP expression by lowering the levels of pro-inflammatory cytokines which would otherwise enhance NF-κB activity and promote T6BP gene transcription. | ||||||
Andrographolide | 5508-58-7 | sc-205594 sc-205594A | 50 mg 100 mg | $15.00 $40.00 | 7 | |
Andrographolide has the potential to reduce T6BP expression due to its inhibitory effects on NF-κB activation, which is necessary for the transcriptional initiation of the T6BP gene. | ||||||
Emodin | 518-82-1 | sc-202601 sc-202601A sc-202601B | 50 mg 250 mg 15 g | $105.00 $214.00 $6255.00 | 2 | |
Emodin can lead to a downregulation of T6BP expression by disrupting the phosphorylation and degradation of IκB, which in turn prevents NF-κB from translocating to the nucleus and promoting T6BP transcription. | ||||||
Ursolic Acid | 77-52-1 | sc-200383 sc-200383A | 50 mg 250 mg | $56.00 $180.00 | 8 | |
Ursolic acid might inhibit T6BP expression by hindering the activation of NF-κB, a transcription factor responsible for the induction of the T6BP gene, thus leading to decreased T6BP protein levels. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A is known to inhibit NF-κB activation through multiple mechanisms, thereby potentially leading to a decrease in the transcription and subsequent expression of T6BP. | ||||||
Caffeic acid phenethyl ester | 104594-70-9 | sc-200800 sc-200800A sc-200800B | 20 mg 100 mg 1 g | $71.00 $296.00 $612.00 | 19 | |
Caffeic acid phenethyl ester (CAPE) is known to inhibit the DNA-binding activity of NF-κB, thereby potentially reducing the expression of T6BP by preventing NF-κB from activating T6BP gene transcription. | ||||||
Anacardic Acid | 16611-84-0 | sc-202463 sc-202463A | 5 mg 25 mg | $102.00 $204.00 | 13 | |
Anacardic acid may inhibit T6BP expression by blocking the activation of NF-κB, which is crucial for the transcriptional upregulation of the T6BP gene during inflammatory signaling pathways. | ||||||